Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1347691
Species: Homo sapiens
RGD Object: Gene
Symbol: FASN
Name: fatty acid synthase
Acc ID: CHEBI:94686
Term: orlistat
Definition: A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.
Chemical ID: MESH:C055122
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
FASNaffects bindingEXP 6480464CTDorlistat analog binds to FASN proteinPMID:20577697
FASNaffects response to substanceEXP 6480464CTDFASN protein affects the susceptibility to orlistatPMID:15870086
FASNdecreases activityEXP 6480464CTDorlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN proteinPMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:18710210 PMID:18723500
FASNdecreases expressionEXP 6480464CTDOrlistat results in decreased expression of FASN proteinPMID:30667213 PMID:32045588
FASNmultiple interactionsEXP 6480464CTD[Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone]PMID:15138278 PMID:17012255 PMID:17618296 PMID:17847090 PMID:18281512 PMID:18723500 PMID:20148945 PMID:32045588 PMID:33476690
FASNdecreases activityISOFasn (Mus musculus)6480464CTDorlistat results in decreased activity of FASN proteinPMID:21213365
FASNmultiple interactionsISOFasn (Mus musculus)6480464CTD[orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid]PMID:21213365
Go Back to source page   Continue to Ontology report